Multiple Myeloma Awareness Month: The Current and Future Landscape

Why It Matters

The expanding therapeutic landscape and looming patent expiries create both clinical breakthroughs for patients and strategic openings for pharma companies.

Key Takeaways

• 85k new cases, 330k prevalent in 8 markets 2026
• MM drug sales forecast $29.9bn by 2032
• CAR‑T and mezigdomide trials reshape later‑line therapy
• Revlimid, Darzalex patents expire 2027‑2029
• 80 Phase II/III trials indicate robust pipeline

Pulse Analysis

Multiple myeloma remains a high‑impact blood cancer, with incidence rising across the United States, Europe and Asia. Awareness initiatives in March aim to shorten the diagnostic lag that often delays treatment, improving survival odds. As the disease burden climbs, payers and providers are increasingly focused on therapies that can deliver deep, durable responses while managing cost pressures.

The commercial outlook reflects this urgency. GlobalData forecasts the eight‑market (8MM) MM drug market to reach $29.9 bn by 2032, up from $25.5 bn in 2026. A notable shift is occurring toward second‑line and later therapies, spurred by recent approvals of CAR‑T products like Carvykti and Tecvayli. The impending expiry of Revlimid (2027) and Darzalex (2029) patents will further open the market to biosimilars and next‑generation agents, intensifying competition and innovation.

Clinical activity underscores the momentum. Eighty Phase II/III trials are underway, with Kite’s iMMagine‑1 CAR‑T leveraging a compact D‑domain to boost CAR density and cytotoxicity, projected to generate $658 m in 2032 sales. Simultaneously, Bristol Myers Squibb’s mezigdomide, a next‑generation cereblon E3 ligase modulator, shows 75‑85% response rates in heavily pre‑treated patients and is expected to capture $241 m by 2032. These pipelines not only promise extended remissions for patients but also signal lucrative entry points for innovators seeking to capture market share as legacy drugs lose exclusivity.